The IL6R single nucleotide polymorphism (SNP) rs2228145 leads to increased proteolysis of its product and a reduction in classic signaling, and has similar directional effects to an existing anti-IL6R monoclonal antibody, tocilizumab (licensed for the treatment of rheumatoid arthritis); these include accumulation of circulating IL6 and s-IL6R levels, most likely due to reduced clearance of IL6 via its receptor in the liver and termination of negative feedback mechanisms, as well as a reduction in downstream inflammatory biomarkers, such as C-reactive protein, platelets, and fibrinogen.3 The gene discussed is IL6; the disease is rheumatoid arthritis.